Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ --...